Pathstone Family Office’s Acumen Pharmaceuticals ABOS Stock Holding History

Pathstone Family Office’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.99M	Buy	478,790 +11,730	+3%	+$72.5K	0.02%	476
2023 Q2	$2.25M	Buy	467,060 +75,000	+19%	+$359K	0.03%	297
2023 Q1	$1.59M	Sell	392,060 -668,600	-63%	-$3.49M	0.03%	332
2022 Q4	$5.73M	Buy	1,060,660 +554,120	+109%	+$3.72M	0.05%	261
2022 Q3	$5.08M	Buy	+506,540	New	+$2.91M	0.05%	231

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Family Office's ABOS Position: Q3 2023 in Review

Pathstone Family Office increased its Acumen Pharmaceuticals (ABOS) stake by 2.5% in Q3 2023, buying an estimated $72.5K and bringing the position to 478,790 shares worth $1.99M. The position accounts for 0.02% of the portfolio, ranked #476.

Pathstone Family Office first reported a position in ABOS in Q3 2022 and has held it in 5 quarters since. The position peaked at $5.73M in Q4 2022. 66 funds tracked by Wall St. Rank hold ABOS as of Q3 2023.

Pathstone Family Office held 478,790 shares of Acumen Pharmaceuticals worth $1.99M as of Q3 2023.
Pathstone Family Office bought 11,730 Acumen Pharmaceuticals shares in Q3 2023, an estimated $72.5K.
Acumen Pharmaceuticals made up 0.02% of Pathstone Family Office's portfolio in Q3 2023, its #476 holding.
Pathstone Family Office first reported a position in Acumen Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
Pathstone Family Office's Acumen Pharmaceuticals position peaked at $5.73M in Q4 2022.
66 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.